Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Feb 14, 2018 (9 years ago)

Bella Capsules

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Marketed Without An Approved NDA/ANDA: This product contains undeclared sibutramine. The presence of sibutramine, a previously approved controlled substance that was withdrawn from the U.S. market in October 2010 due to safety concerns, in this tainted product renders it an unapproved drug for which safety and efficacy have not been established and therefore subject to recall.

Cause type: Chemical / undeclared

A chemical that should not be there - benzene, methanol, lead - or an undeclared prescription drug hidden in a supplement. The label gives no warning: you may be taking a toxic solvent, a heavy metal, or a drug such as sildenafil that interacts with your other medicines. All chemical / undeclared recalls.

What was recalled

Bella Capsules, 600mg, 30-count bottles, Manufactured for: Bella All Natural 304 E 11th Street, Los Angeles, CA 90015

Recalling firm
Bella All Natural
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0593-2018 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other chemical / undeclared recalls from 2018

All chemical / undeclared recalls
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-363-90 D-1106-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-362-90 D-1105-2018
Class III · Low risk

Valsartan Tablets USP

Incorrect/Undeclared Excipient: There is a potential an incorrect grade of excipient was used during manufacturing.

Terminated Chemical / undeclared Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-361-90 D-1104-2018